HilleVax to Participate in J.P. Morgan Biotech – 2022 Conference Call Series

Rhea-AI Summary

BOSTON, Sept. 1, 2022 - HilleVax, a clinical-stage biopharmaceutical company, will participate in the J.P. Morgan Biotech – 2022 Conference Call Series on September 6, 2022. Key topics will include HIL-214, an investigational virus-like particle vaccine aimed at preventing moderate-to-severe norovirus-related acute gastroenteritis, and its ongoing Phase 2b study NEST-IN1. The fireside chat will be moderated by Eric Joseph, Ph.D., featuring CEO Robert Hershberg.

Norovirus accounts for over 700 million cases of acute gastroenteritis globally, resulting in significant health costs.

BOSTON, Sept. 01, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the J.P Morgan Biotech – 2022 Conference Call Series. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b study NEST-IN1 will be topics of discussion.

Fireside chat details:
Date:			Tuesday, September 6, 2022
Time:			1:00 – 2:00 p.m. Eastern Daylight Time (EDT)
Moderator:			Eric Joseph, Ph.D.
HilleVax Participant:			Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer

Please contact your J.P. Morgan representative to access the session

About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over $4 billion in direct health system costs and $60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company’s website at http://www.HilleVax.com.

Contact:

Shane Maltbie
IR@hillevax.com
+1-617-213-5054

FAQ

What is HilleVax's involvement in the J.P. Morgan Biotech – 2022 Conference?

HilleVax will participate in the J.P. Morgan Biotech – 2022 Conference Call Series on September 6, 2022.

What topics will be discussed during HilleVax's conference call?

The conference call will discuss HIL-214, a vaccine for norovirus-related acute gastroenteritis, and the Phase 2b study NEST-IN1.

When is HilleVax's conference call scheduled?

The conference call is scheduled for September 6, 2022, from 1:00 to 2:00 p.m. EDT.

Who will moderate HilleVax's conference call?

The fireside chat will be moderated by Eric Joseph, Ph.D.

What is HIL-214 and its significance?

HIL-214 is a virus-like particle vaccine candidate aimed at preventing moderate-to-severe norovirus-related acute gastroenteritis, a significant global health issue.